1. Increasing demand for lyophilized injectable drugs due to their extended shelf life and improved stability.
2. Rising prevalence of chronic diseases driving the need for injectable medications that can be easily stored and transported.
3. Technological advancements in lyophilization techniques leading to the development of more effective and efficient drug formulations.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Drug Type, Indication, Delivery Type, Packaging, Distribution Channel |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Pfizer, Novartis AG, Roche Holding AG, Johnson & Johnson, Sanofi S.A., Amgen, AbbVie, Merck & Co.,, Eli Lilly and Company, AstraZeneca PLC, Bristol Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences,, Biogen, Teva Pharmaceutical Industries., Mylan N.V., Celgene, Novo Nordisk A/S, Vertex Pharmaceuticals Incorporated, Takeda Pharmaceutical Company Limited |
1. High cost associated with lyophilization process and equipment leading to increased production expenses.
2. Strict regulatory requirements and quality standards for lyophilized injectable drugs increasing the time and resources required for product development and approval.